前收市價 | 15.06 |
開市 | 15.00 |
買盤 | 14.68 x 600 |
賣出價 | 14.77 x 100 |
今日波幅 | 13.96 - 15.15 |
52 週波幅 | 5.56 - 21.17 |
成交量 | |
平均成交量 | 837,816 |
市值 | 1.172B |
Beta 值 (5 年,每月) | 0.89 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.99 |
業績公佈日 | 2024年8月07日 - 2024年8月12日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 26.25 |
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment. The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity
In this article, we will take a detailed look at Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Paul Tudor Jones and Insiders Love These 5 Stocks. In an interview given to the Palm Beach Civic Association in January 2024, billionaire Paul Tudor Jones said that […]
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity’s future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction. While many treatments help extend your life if leveraged properly and consistently — namely, diet and exercise — the most compelling longevity stocks address specific age-associated ailments instead. As we age, rapid neurological and physical degenera